|Bid||322.55 x 900|
|Ask||405.50 x 1400|
|Day's Range||362.58 - 368.20|
|52 Week Range||281.89 - 526.12|
|PE Ratio (TTM)||29.84|
|Earnings Date||Aug 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||379.55|
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on PTLA sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are the following equities: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Recro Pharma Inc. (NASDAQ: REPH), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN).
After sustaining an uptrend on the markets since bottoming in February, GlaxoSmithKline (NYSE:GSK) still has an attractive profile for income and value investors. The stock’s rock-solid dividend and its growth potential from a number of positive wins suggest GSK stock will still climb higher.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
According to Incyte Corporation (INCY), the firm is a “Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.”
TARRYTOWN, N.Y. , July 9, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its second quarter 2018 financial and operating results on Thursday, August ...
Ionis Pharmaceuticals (IONS), an RNA1-targeted therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies. In Q1 2018, Ionis’s revenue grew 24.7% YoY (year-over-year) to $144.4 million from $115.8 million.
On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10. On June 26, Exelixis stock rose ~8.0% to close at $21.03 from its previous day’s close of $19.54 on June 25.
In the week that ended on June 29, Vertex Pharmaceuticals (VRTX) stock closed at $169.96, which represented a ~7% rise from its previous week’s close of $159.76. On June 29, Vertex Pharmaceuticals’ stock price rose 15.16% to reach $169.96 from its previous day’s close of $147.59. In June, Vertex Pharmaceuticals announced that its cystic fibrosis drug Orkambi would be reimbursed in Sweden.
Regeneron Pharmaceuticals and Sanofi made a first-ever price increase for Dupixent, a potential blockbuster eczema treatment, an analyst said Monday.
Shares of Regeneron Pharmaceuticals, Inc. ( REGN) have been hammered over the past year, falling by nearly 30 percent while the S&P 500 has risen about 12 percent. The better prospects for the stock partly reflects improving fundamentals as analysts boost their earnings and revenue forecasts. The raised estimates come even as analysts have lowered the average price target of the stock.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Over the last one-month, outflows of investor capital in ETFs holding REGN totaled $1.26 billion.
The e-commerce giant said it was acquiring online pharmacy PillPack, sending traditional pharmacy stocks like CVS Health (NYSE:CVS), Rite Aid (NYSE:RAD) and Walgreens Boots Alliance (NASDAQ:WBA) careening. Rather, the best bets from here are Sherwin-Williams (NYSE:SHW), Regeneron (NASDAQ:REGN) and Allstate (NYSE:ALL), each of which are relatively immune to the market’s normal recycling of hysteria.
Shares of Regeneron Pharmaceuticals (REGN) have been in a slump, falling nearly 10% so far this year, and 33.5% in the past 12 months. Analyst Hartaj Singh upgraded the stock to Outperform from Perform, with a $410 price target on Tuesday. Singh writes that Regeneron is now "on the cusp" of strong 2019 and 2020 sales growth, helped by its macular-degeneration treatment Eylea being used more for diabetic macular edema treatment and its expansion to nonproliferative diabetic retinopathy next year.
No matter how old you are, no matter how wealthy you are, you should really have some money socked away in the stock market, Jim Cramer told his Mad Money viewers Tuesday, as he dedicated the entire show to generational investing, or how to handle your finances at every age. Cramer said the stock market is still the best ladder we have for social mobility. Or, put another way, if you invest $10,000 today, 40 years from now that investment could be worth $450,000.
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s returnRead More...
In the first quarter, Regeneron (REGN) and Sanofi’s (SNY) Dupixent witnessed global sales of close to $131 million, of which $117 million came from US markets. Because there was an increase in the drug’s inventory levels at the end of 2017, Dupixent reported a sequential fall in revenue in the first quarter of 2018. Further, in the first year of its launch, ~83% of patients who started on Dupixent therapy chose to remain on this regimen.
Regeneron (REGN) plans to submit a supplemental biologics license application (or sBLA) to the FDA seeking approval for Eylea in diabetic retinopathy (or DR) without Diabetic Macular Edema (or DME) in late 2018. DR without DME affects almost 3.5 million people in the United States.
Regeneron (REGN) is focused on advancing Eylea in the diabetic retinal disease segment, an area with significant unmet demand due to the rising prevalence of diabetes. The drug has emerged as the leading branded anti-vascular endothelial growth factor (or anti-VEGF) therapy for Diabetic Macular Edema (or DME). In February 2015, the company declared favorable results for Eylea from the National Institutes of Health’s sponsored comparative effectiveness study involving patients suffering from DME.
In its first-quarter conference call, Regeneron (REGN) reduced the projected range for its 2018 non-GAAP (generally accepted accounting principles) selling, general, and administrative (or SG&A) expenses from its previous guidance of $1.35 billion–$1.45 billion to $1.33 billion–$1.40 billion. The company continues to anticipate higher SG&A expenses in 2018 on a YoY (year-over-year) basis due to the commercial launches of Kevzara and Dupixent and increasing commercialization expenses for Eylea. The company’s rising focus on expanding Eylea’s label in diabetic eye diseases and commercialization expenses attributable to probable FDA approvals for dupilumab in asthma indications and cemiplimab in cutaneous squamous-cell carcinoma indications may also result in higher SG&A expenses in 2018 compared to 2017.
Regeneron’s (REGN) Eylea has continued to be the leading anti-vascular endothelial growth factor (or anti-VEGF) agent for the treatment of retinal diseases in 2018. The drug was approved by the FDA in November 2011 for wet age-related macular degeneration (or wet AMD), in July 2014 for Diabetic Macular Edema (or DME), and in March 2015 for diabetic retinopathy in patients with DME. In the first quarter, Eylea reported sales of close to $1.6 billion, and its total doses administered globally since its launch reached 15 million.
On June 19, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, Solid Biosciences’ stock price hit a 52-week high of $54.84.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...
Sanofi (SASY.PA) missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche (ROG.S) to head its group research operations. Dmitri Wiederschain, head of Sanofi's immuno-oncology research, acknowledged the company had failed to capitalise on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumour cells - in the early 2010s.